Aspire Biopharma (NASDAQ:ASBP – Get Free Report) and Worksport (NASDAQ:WKSP – Get Free Report) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
Valuation & Earnings
This table compares Aspire Biopharma and Worksport”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspire Biopharma | $10,000.00 | 1,229.20 | -$24.48 million | ($69.62) | -0.13 |
| Worksport | $16.10 million | 0.44 | -$19.35 million | ($2.34) | -0.15 |
Worksport has higher revenue and earnings than Aspire Biopharma. Worksport is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Aspire Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, Worksport has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
Profitability
This table compares Aspire Biopharma and Worksport’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
| Worksport | -114.49% | -102.57% | -73.69% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Aspire Biopharma and Worksport, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Worksport | 1 | 0 | 1 | 0 | 2.00 |
Worksport has a consensus target price of $2.00, indicating a potential upside of 466.25%. Given Worksport’s stronger consensus rating and higher possible upside, analysts plainly believe Worksport is more favorable than Aspire Biopharma.
Insider and Institutional Ownership
19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 16.1% of Worksport shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 5.8% of Worksport shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Worksport beats Aspire Biopharma on 10 of the 14 factors compared between the two stocks.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
About Worksport
Worksport Ltd., through its subsidiary, designs and distributes truck tonneau covers in Canada and the United States. The company offers soft tonneau covers, such as vinyl wrapped tri- and quad-fold tonneau covers; and hard tonneau covers, including tri- and quad-fold aluminum covers. It also offers energy products, such as Worksport SOLIS, a tonneau cover with integrated solar panels; and Worksport COR energy storage system, a modular, portable power station. It serves its products to automotive accessories, consumer electronics, and residential and commercial HVAC system markets. The company also sells its products through wholesalers, private labels, distributors, and online retail channels, including eBay, Amazon, Walmart, and e-commerce platform hosted on Shopify. Worksport Ltd. is based in West Seneca, New York.
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
